Owlstone Medical, a pioneering leader in non-invasive diagnostic technology, has successfully secured $27 million in funding to advance its revolutionary Breath Biopsy® platform. The funding will fuel the development of its breathalyzer for disease, which aims to transform the early detection and precision medicine landscape for various health conditions, including respiratory diseases, liver ailments, cancer, and digestive issues. With a mission to save 100,000 lives and significantly reduce healthcare costs by $1.5 billion, Owlstone Medical is on the forefront of biomarker discovery and validation, harnessing the power of volatile organic compounds (VOCs) in breath samples through its award-winning ReCIVA® Breath Sampler.
The company is committed to making diagnostic testing more accessible and efficient, leveraging state-of-the-art chemical analysis technologies and its proprietary microchip sensor technology, FAIMS, to identify validated disease biomarkers. As global health concerns rapidly evolve, particularly around lung cancer, asthma, and liver disease, Owlstone Medical is actively participating in collaborative research partnerships to expand its reach and impact. The breath biopsy solutions developed will not only support academic, clinical, and pharmaceutical research but will also open new avenues for patients to receive timely diagnoses when treatment options are most effective. While the Breath Biopsy Products and Services are currently designated for research use only, the ongoing advancements hold great promise for the future of medical diagnostics. Owlstone Medical is poised to redefine how we think about and approach early disease detection, and this latest funding round propels them closer to achieving that goal.
